These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7519696)

  • 21. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension.
    Morgan TO; Anderson AI; MacInnis RJ
    Am J Hypertens; 2001 Mar; 14(3):241-7. PubMed ID: 11281235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?
    Jespersen CM
    Cardiologia; 1995 Dec; 40(12 Suppl 1):307-10. PubMed ID: 8903054
    [No Abstract]   [Full Text] [Related]  

  • 23. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD; Udelson JE; Konstam MA
    Curr Opin Cardiol; 1998 May; 13(3):162-7. PubMed ID: 9649938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy for hypertension associated with heart failure].
    Miyamoto H; Imaizumi T
    Nihon Naika Gakkai Zasshi; 2003 Feb; 92(2):258-63. PubMed ID: 12652730
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
    Boydak B; Nalbantgil S; Yilmaz H; Zoghi M; Ozerkan F; Nalbantgil I; Onder R
    Saudi Med J; 2004 Dec; 25(12):1975-8. PubMed ID: 15711679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of angiotensin-converting enzyme inhibitors in left ventricular dysfunction: results of the studies of left ventricular dysfunction in the context of other similar trials.
    Yusuf S; Garg R; McConachie D
    J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S28-35. PubMed ID: 7514238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?
    Cleland JG; Puri S
    Br Heart J; 1994 Sep; 72(3 Suppl):S81-6. PubMed ID: 7946810
    [No Abstract]   [Full Text] [Related]  

  • 28. Calcium channel blockers: an evidence-based review.
    Waters D
    Can J Cardiol; 1997 Aug; 13(8):757-66. PubMed ID: 9284842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium channel blockers in cardiac failure.
    Mahon N; McKenna WJ
    Prog Cardiovasc Dis; 1998; 41(3):191-206. PubMed ID: 9872606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).
    Schmieder RE; Schlaich MP; Klingbeil AU; Martus P
    Nephrol Dial Transplant; 1998 Mar; 13(3):564-9. PubMed ID: 9550628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2005 Jan; 125(1):38-40. PubMed ID: 15643463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
    McKelvie R; McConachie D; Yusuf S
    Eur Heart J; 1994 May; 15 Suppl B():9-13; discussion 26-30. PubMed ID: 8076660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.
    Seeland U; Kouchi I; Zolk O; Jockenhövel F; Itter G; Linz W; Böhm M
    Eur J Heart Fail; 2003 Jun; 5(3):241-6. PubMed ID: 12798820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ventricular remodeling and angiotensin-converting enzyme inhibitors.
    Goldstein S; Sabbah H
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S27-31. PubMed ID: 7700061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands.
    Morisco C; Lembo G; Sarno D; Argenziano L; Fratta L; Rozza F; Trimarco B
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S27-33. PubMed ID: 9605599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group.
    Hansen JF; Hagerup L; Sigurd B; Pedersen F; Mellemgaard K; Pedersen-Bjergaard O; Mortensen LS
    Am J Cardiol; 1997 Mar; 79(6):738-41. PubMed ID: 9070551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of calcium antagonists in ischaemic heart disease.
    Pepine CJ
    Eur Heart J; 1995 Aug; 16 Suppl H():19-24. PubMed ID: 8846801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction?
    Ball SG; Hall AS
    Am Heart J; 1996 Jul; 132(1 Pt 2 Su):244-50. PubMed ID: 8677863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.